knowledge -WSS

knowledge

author：leisure time 2025-10-01 21:40:30 - browse：2778

U.S. President Joe Biden stands with his fingers locked next to an US flag — politics coverage from STAT — President Biden's White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs.

WASHINGTON — The White House on Monday ballyhooed a routine step in Medicare’s new program to negotiate the prices of prescription drugs, its latest effort to draw attention to the program in an election year.

The news is not controversial: The pharmaceutical companies that make the first ten drugs up for negotiation all submitted counteroffers. It’s an incremental step in the new program, which was created in 2022.

Earlier this year, Medicare sent its initial price offers to the companies. Neither the Biden administration nor the drug manufacturers have volunteered any information about the White House’s initial price offers or the counteroffers. The process is scheduled to end by Aug. 1.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： GSK Flovent asthma inhalers replaced by authorized generics

WSS

Surge in Apellis stock fueled by confidence in safety of its eye drug

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Why psychiatrists like me stop taking insurance

Montana youths win climate lawsuit against state for promoting fossil fuels

Dozens dead from Maui wildfires: What we know about the victims

AdventHealth escalates lawsuit against insurance vendor Multiplan

focus

knowledge

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Surge in Apellis stock fueled by confidence in safety of its eye drug

Walensky prepares to leave CDC — and Congress — behind

Senators push IRS to launch nonprofit hospital probe

Cancer drug shortages should be causing more outrage

Illumina slashes 2023 revenue projections yet again

23andMe had bad news about my health. I wish a person had delivered it

Antibiotic resistance and the global rise in human conflict

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Patients, digital health players weigh in on FTC's data privacy plan

explore

YouTube cracks down on misinformation on cancer treatment

J&J to buy cancer drug developer Ambrx Biopharma

What to know about the judge who will handle the Trump case

Schizophrenia gene found to be linked to cells' energy dysfunction

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

3 trends to watch in health tech's hiring outlook for 2024

entertainment

leisure time

explore

knowledge